{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:22:15Z","timestamp":1794604935497,"version":"4.9.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>This retrospective real-world study investigated the clinical use of the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor) ratio alone or in combination with other clinical tests to predict an adverse maternal (maternal death, kidney failure, hemolysis elevated liver enzymes low platelets-syndrome, pulmonary edema, disseminated intravascular coagulation, cerebral hemorrhage, or eclampsia) or fetal (delivery before 34 weeks because of preeclampsia and\/or intrauterine growth restriction, respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage, placental abruption or intrauterine fetal death or neonatal death within 7 days post natum) pregnancy outcome in patients with signs and symptoms of preeclampsia. We evaluated the sFlt-1\/PlGF-ratio cutoff values of 38 and 85 and evaluated its integration into a multimarker model. Of 1117 subjects, 322 (28.8%) developed an adverse fetal or maternal outcome. Patients with an adverse versus no adverse outcome had a median sFlt-1\/PlGF-ratio of 177 (interquartile range, 54\u2013362) versus 14 (4\u201364). Risk-stratification with the sFlt-1\/PlGF cutoff values into high- (&gt;85), intermediate- (38\u201385), and low-risk (&lt;38) showed a significantly shorter time to delivery in high- and intermediate- versus low-risk patients (4 versus 8 versus 29 days). When integrating all available clinical information into a multimarker model, an area under the curve of 88.7% corresponding to a sensitivity, specificity, positive and negative predictive value of 80.0%, 87.3%, 75.0%, and 90.2% was reached. The sFlt-1\/PlGF-ratio alone was inferior to the full model with an area under the curve of 85.7%. As expected, blood pressure and proteinuria were significantly less accurate with an area under the curve of 69.0%. Combining biomarker measurements with all available information in a multimarker modeling approach increased detection of adverse outcomes in women with suspected disease.<\/jats:p>","DOI":"10.1161\/hypertensionaha.120.15146","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T05:14:44Z","timestamp":1607318084000},"page":"461-471","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":163,"title":["Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)\/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine"],"prefix":"10.1161","volume":"77","author":[{"given":"Lisa Antonia","family":"Dr\u00f6ge","sequence":"first","affiliation":[{"name":"From the Department of Obstetrics (L.A.D., N.S., L.F., W.H., S.V.), Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Holger","family":"Perschel","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Clinical Chemistry, and Pathobiochemistry (F.H.P.), Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Berlin, Germany"},{"name":"Labor Berlin - Charit\u00e9 Vivantes GmbH, Berlin, Germany (F.H.P.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"St\u00fctz","sequence":"additional","affiliation":[{"name":"From the Department of Obstetrics (L.A.D., N.S., L.F., W.H., S.V.), Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5577-3236","authenticated-orcid":true,"given":"Anna","family":"Gafron","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Evangelisches Krankenhaus Paul Gerhardt Stift, Lutherstadt Wittenberg (A.G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Frank","sequence":"additional","affiliation":[{"name":"Labor Berlin - Charit\u00e9 Vivantes GmbH, Berlin, Germany (F.H.P.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Busjahn","sequence":"additional","affiliation":[{"name":"HealthTwiSt GmbH, Berlin, Germany (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Henrich","sequence":"additional","affiliation":[{"name":"From the Department of Obstetrics (L.A.D., N.S., L.F., W.H., S.V.), Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-8636","authenticated-orcid":true,"given":"Stefan","family":"Verlohren","sequence":"additional","affiliation":[{"name":"From the Department of Obstetrics (L.A.D., N.S., L.F., W.H., S.V.), Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2010.10.004"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2018.05.004"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0029-7844(00)01125-x"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000437382.03963.88"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","unstructured":"Gestational hypertension and preeclampsia obstetrics & gynecology. 2020;135:1492\u20131495. doi: 10.1097\/AOG.0000000000003892","DOI":"10.1097\/AOG.0000000000003892"},{"key":"e_1_3_5_7_2","unstructured":"Hypertensive Pregnancy Disorders: Diagnosis and Therapy. Guideline of the German Society of Gynecology and Obstetrics (S2k-Level AWMF-Registry No. 015\/018 March 2019). Accessed April 1 2020. http:\/\/www.awmf.org\/leitlinien\/detail\/ll\/015-018.html"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70227-X"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414838"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.054361"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.09.016"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2018.06.017"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2016.08.036"},{"key":"e_1_3_5_14_2","unstructured":"Surbek D Hodel M Baumann M Lapaire O. Anwendung des sFlt-1\/PlGF Tests zur Pr.eklampsie-Diagnostik. Akademie f\u00fcr fetomaternale Medizin (AFMM) der SGGG\/gyn\u00e9cologie Suisse 2019. Accessed April 1 2020. https:\/\/www.sggg.ch\/fileadmin\/user_upload\/67_Diagnostik_Praeeklampsie.pdf."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2014.02.001"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2000.107928"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-118908"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pd.4554"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.12371"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.21867"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.17307"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13997"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61351-7"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.01.235"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.19111"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.20346"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.09913"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641955.2013.784788"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.21869"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.14799"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01787"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.19077"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.17310"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08620"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.120.15146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:35:53Z","timestamp":1715582153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.120.15146"}},"subtitle":["A Real-World Study"],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.120.15146"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.120.15146","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"2020-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}